Tags

Type your tag names separated by a space and hit enter

Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Headache. 2018 11; 58 Suppl 3:276-290.H

Abstract

OBJECTIVE

To briefly update and correct the available data on anti-calcitonin gene-related peptide (CGRP) therapies for headache since the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.

BACKGROUND

CGRP is a target for primary headache therapies.

METHODS

The author briefly reviews the new data and publications on gepants and anti-CGRP and anti-CGRP receptor monoclonal antibodies since the writing of his previous review in May 2018, with an emphasis on data provided at the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.

RESULTS

The US Food and Drug Administration (FDA) approved erenumab-aooe, an anti-CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018. On September 14, 2018, the FDA approved fremanezumab-vfrm and on September 26, 2018, the FDA approved galcanezumab-gnlm, both anti-CGRP ligand monoclonal antibodies for the prevention of migraine. Galcanezumab showed effectiveness in preventing episodic cluster headache as well, although has not yet been submitted to the FDA for this indication. Both galcanezumab and fremanezumab failed to prevent chronic cluster headache. Eptinezumab will likely be submitted to the FDA for prevention of migraine later in 2018. Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the FDA for this indication. A press release with data on the effectiveness of daily atogepant in migraine prevention provides some details. An announcement at the meeting suggests daily rimegepant will be tested for prevention as well.

CONCLUSIONS

The development of anti-CGRP therapies opens a new era in the acute and preventive treatment of primary headache disorders.

Authors+Show Affiliations

Geisel School of Medicine at Dartmouth, Hanover, NH, USA. Dartmouth Headache Center, Neurology Department, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30403405

Citation

Tepper, Stewart J.. "Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update On a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018." Headache, vol. 58 Suppl 3, 2018, pp. 276-290.
Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58 Suppl 3:276-290.
Tepper, S. J. (2018). Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache, 58 Suppl 3, 276-290. https://doi.org/10.1111/head.13417
Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update On a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58 Suppl 3:276-290. PubMed PMID: 30403405.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. A1 - Tepper,Stewart J, PY - 2018/09/17/accepted PY - 2018/11/8/entrez PY - 2018/11/8/pubmed PY - 2019/11/9/medline KW - CGRP KW - calcitonin gene-related peptide KW - cluster headache KW - gepants KW - migraine KW - monoclonal antibodies SP - 276 EP - 290 JF - Headache JO - Headache VL - 58 Suppl 3 N2 - OBJECTIVE: To briefly update and correct the available data on anti-calcitonin gene-related peptide (CGRP) therapies for headache since the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. BACKGROUND: CGRP is a target for primary headache therapies. METHODS: The author briefly reviews the new data and publications on gepants and anti-CGRP and anti-CGRP receptor monoclonal antibodies since the writing of his previous review in May 2018, with an emphasis on data provided at the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. RESULTS: The US Food and Drug Administration (FDA) approved erenumab-aooe, an anti-CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018. On September 14, 2018, the FDA approved fremanezumab-vfrm and on September 26, 2018, the FDA approved galcanezumab-gnlm, both anti-CGRP ligand monoclonal antibodies for the prevention of migraine. Galcanezumab showed effectiveness in preventing episodic cluster headache as well, although has not yet been submitted to the FDA for this indication. Both galcanezumab and fremanezumab failed to prevent chronic cluster headache. Eptinezumab will likely be submitted to the FDA for prevention of migraine later in 2018. Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the FDA for this indication. A press release with data on the effectiveness of daily atogepant in migraine prevention provides some details. An announcement at the meeting suggests daily rimegepant will be tested for prevention as well. CONCLUSIONS: The development of anti-CGRP therapies opens a new era in the acute and preventive treatment of primary headache disorders. SN - 1526-4610 UR - https://www.unboundmedicine.com/medline/citation/30403405/Anti_Calcitonin_Gene_Related_Peptide__CGRP__Therapies:_Update_on_a_Previous_Review_After_the_American_Headache_Society_60th_Scientific_Meeting_San_Francisco_June_2018_ L2 - https://doi.org/10.1111/head.13417 DB - PRIME DP - Unbound Medicine ER -